American Bio Medica Receives FDA Clearance.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ: ABMC) today announced that the US Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Rapid One(R) lateral flow immunoassay test for the detection of Cocaine at 150 ng/ml. The Company had previously received clearance to detect Cocaine at 300 ng/ml. This new clearance allows the Company to provide its customers with a more sensitive point of collection test for Cocaine. The Company plans to offer its customers the option of purchasing either detection level for Cocaine.

ABMC Chief Executive Officer Stan Cipkowski stated, "We developed this new test in response to the needs of our customers, particularly those customers in the criminal justice market with "zero tolerance" programs. Once again, this clearance demonstrates ABMC's ability to offer our customers the products they need to develop and implement effective drug testing programs."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R) and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.